{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:31:27Z","timestamp":1791469887832,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Procept BioRobotics"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,6]]},"abstract":"\n Objective<\/jats:title>\n \n To assess the safety and feasibility of aquablation in a first\u2010in\u2010man study. Aquablation is a novel minimally invasive water ablation therapy combining image guidance and robotics (\n AquaBeam<\/jats:sc>\n \u00ae<\/jats:sup>\n ) for the targeted and heat\u2010free removal of prostatic tissue in men with lower urinary tract symptoms (\n LUTS<\/jats:styled-content>\n ) secondary to benign prostatic hyperplasia (\n BPH<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n A prospective, non\u2010randomised, single\u2010centre trial in men aged 50\u201380 years with moderate\u2010to\u2010severe\n LUTS<\/jats:styled-content>\n was conducted. Under real\u2010time image\u2010based ultrasonic guidance,\n AquaBeam<\/jats:sc>\n technology enables surgical planning and mapping, and leads to a controlled heat\u2010free resection of the prostate using a high\u2010velocity saline stream. Patients were evaluated at 1, 3, and 6 months after aquablation.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In all, 15 patients were treated with aquablation under general anaesthesia. The mean (range) age was 73 (59\u201386) years and prostate size was 54 (27\u201385) mL. A substantial median lobe was present in six of the 15 patients. The mean International Prostate Symptom Score (\n IPSS<\/jats:styled-content>\n ) was 23 and the maximum urinary flow rate (\n Q<\/jats:italic>\n max<\/jats:sub>\n ) was 8.4 mL\/s at baseline. The mean procedural time was 48 min with a mean aquablation treatment time of 8 min. All procedures were technically successful with no serious or unexpected adverse events (\n AE<\/jats:styled-content>\n s). All but one patient had removal of catheter on day 1, and most of the patients were discharged on the first postoperative day. No patient required a blood transfusion, and postoperative sodium changes were negligible. There were no serious 30\u2010day\n AE<\/jats:styled-content>\n s. One patient underwent a second aquablation treatment within 90 days of the first procedure. The mean\n IPSS<\/jats:styled-content>\n score statistically improved from 23.1 at baseline to 8.6 at 6 months (\n P<\/jats:italic>\n < 0.001) and the\n Q<\/jats:italic>\n max<\/jats:sub>\n increased from 8.6 mL\/s at baseline to 18.6 mL\/s at the 6\u2010month follow\u2010up (\n P<\/jats:italic>\n < 0.001). At 6 months, the mean detrusor pressure at\n Q<\/jats:italic>\n max<\/jats:sub>\n decreased to 45 cmH\n 2<\/jats:sub>\n 0 from 66 cmH\n 2<\/jats:sub>\n 0 at baseline (\n P<\/jats:italic>\n < 0.05), and the mean prostate size was reduced to 36 mL, a 31% reduction in size vs baseline (\n P<\/jats:italic>\n < 0.001). No cases of urinary incontinence or erectile dysfunction were reported.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These preliminary results from this initial study show aquablation of the prostate is technically feasible with a safety profile comparable to other\n BPH<\/jats:styled-content>\n technologies. The combination of surgical mapping by the operating surgeon and the high\u2010velocity saline provides a promising technique delivering a conformal, quantifiable, and standardised heat\u2010free ablation of the prostate. Advantages of this technique include reduction in resection time compared with other endoscopic methods, as well as the potential to preserve sexual function.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.13358","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T04:25:20Z","timestamp":1445228720000},"page":"923-929","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Aquablation \u2013 image\u2010guided robot\u2010assisted waterjet ablation of the prostate: initial clinical experience"],"prefix":"10.1111","volume":"117","author":[{"given":"Peter","family":"Gilling","sequence":"first","affiliation":[{"name":"Department of Urology Tauranga Hospital Tauranga New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Reuther","sequence":"additional","affiliation":[{"name":"Department of Urology Tauranga Hospital Tauranga New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Kahokehr","sequence":"additional","affiliation":[{"name":"Department of Urology Tauranga Hospital Tauranga New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fraundorfer","sequence":"additional","affiliation":[{"name":"Department of Urology Tauranga Hospital Tauranga New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"14","article-title":"Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations","volume":"10","author":"Roehrborn CG","year":"2008","journal-title":"Rev Urol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35405-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.318"},{"key":"e_1_2_7_5_1","unstructured":"OelkeM BachmannA DescazeaudAet al.Guidelines on the Treatment of Non\u2010neurogenic Male LUTS. European Association of Urology 2011. Available at:http:\/\/uroweb.org\/wp-content\/uploads\/12_Male_LUTS.pdf. Accessed October 2015"},{"key":"e_1_2_7_6_1","unstructured":"McVaryKT RoehrbornCG AvinsALet al.In American Urological Association Guideline Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research Chap 3. Available at:https:\/\/www.auanet.org\/education\/guidelines\/benign-prostatic-hyperplasia.cfm. Accessed October 2015."},{"key":"e_1_2_7_7_1","first-page":"RA94","article-title":"Treatment options for benign prostatic hyperplasia in older men","volume":"14","author":"Miano R","year":"2008","journal-title":"Med Sci Monit"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.042"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2006.08.012"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00908.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800690212"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/1993\/82362"},{"key":"e_1_2_7_13_1","first-page":"2333","article-title":"Laparoscopic liver resection compared with conventional partial hepatectomy \u2013 a prospective analysis","volume":"45","author":"Rau HG","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2002.96.4.0690"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00389793"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/109264202320884126"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67872-X"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0653-8"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09954.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-013-0351-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2014.0304"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.01.074"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00524-X"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12868"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13358","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:27:59Z","timestamp":1761758879000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/bju.13358"],"URL":"https:\/\/doi.org\/10.1111\/bju.13358","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725875369.793554113","asserted-by":"object"}]},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"assertion":[{"value":"2015-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}